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Background: Women with mutations in BRCA1 or BRCA2 are at high risk of developing breast cancer and, in British
Columbia, Canada, are offered screening with both magnetic resonance imaging (MRI) and mammography to
facilitate early detection. MRI is more sensitive than mammography but is more costly and produces more false
positive results. The purpose of this study was to calculate the cost-effectiveness of MRI screening for breast cancer
in BRCA1/2 mutation carriers in a Canadian setting.
Methods: We constructed a Markov model of annual MRI and mammography screening for BRCA1/2 carriers, using
local data and published values. We calculated cost-effectiveness as cost per quality-adjusted life-year gained
(QALY), and conducted one-way and probabilistic sensitivity analysis.
Results: The incremental cost-effectiveness ratio (ICER) of annual mammography plus MRI screening, compared to
annual mammography alone, was $50,900/QALY. After incorporating parameter uncertainty, MRI screening is
expected to be a cost-effective option 86% of the time at a willingness-to-pay of $100,000/QALY, and 53% of the
time at a willingness-to-pay of $50,000/QALY. The model is highly sensitive to the cost of MRI; as the cost is
increased from $200 to $700 per scan, the ICER ranges from $37,100/QALY to $133,000/QALY.
Conclusions: The cost-effectiveness of using MRI and mammography in combination to screen for breast cancer in
BRCA1/2 mutation carriers is finely balanced. The sensitivity of the results to the cost of the MRI screen itself
warrants consideration: in jurisdictions with higher MRI costs, screening may not be a cost-effective use of
resources, but improving the efficiency of MRI screening will also improve cost-effectiveness.
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Carriers of BRCA1 or BRCA2 (BRCA1/2) mutations are at
particularly high risk of breast cancer, with a 45-65% cu-
mulative risk by age 70 years [1,2]. In current practice at
the British Columbia Cancer Agency (BCCA), women with
a strong family history of breast and ovarian cancer who
meet specific eligibility criteria [3] may be referred to the
Hereditary Cancer Program to receive genetic counseling
and testing for BRCA1/2 mutations. Women with a
BRCA1/2 mutation may significantly reduce their risk of
breast cancer by opting to undergo prophylactic bilateral* Correspondence: speacock@bccrc.ca
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reproduction in any medium, provided the ormastectomy and/or bilateral oophorectomy [4-7], but
many factors are involved in choosing risk-reducing sur-
gery [8] and many women instead opt for early detection
strategies, including regular screening with MRI and
mammography [9]. Since 2003, the BCCA has operated a
high-risk screening clinic, offering annual breast cancer
screening with MRI and mammography to confirmed
BRCA1/2 mutation carriers.
MRI is more sensitive than mammography for breast
cancer screening in BRCA1/2 mutation carriers, with
screening trials indicating that between 89-100% of breast
cancers were detected with the combination of mammog-
raphy and MRI, versus 33-50% with mammography alone
[10-18]. However, the specificity of MRI is lower thanLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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91-99% for mammography alone [10-18]), giving rise to
more false positive screens, which may increase costs
and negatively impact quality of life for screening partici-
pants [19]. Breast MRI is more expensive than mammog-
raphy, but there is little evidence available on the
cost-effectiveness of MRI for breast cancer screening in
Canada. Estimates from the United States of incremental
cost per quality adjusted life year (QALY) for the addition
of MRI to annual mammography screening range widely,
from $55,420/QALY [20] and $69,125/QALY [21] for
BRCA1 carriers, $130,695/QALY BRCA2 carriers [20], and
$179,599/QALY for women with >15% lifetime risk [22]
(all values USD). Cost-effectiveness ratios are particularly
sensitive to the unit cost of an MRI screening test [21-23]
and to the breast cancer risk in the population being
screened [20,24]. In order to better understand the context
of MRI screening at the BCCA, the investigators deter-
mined a local cost-effectiveness analysis was warranted.
The objective of this study is to estimate the cost-
effectiveness of annual mammography plus MRI screening
for breast cancer in BRCA1/2 mutation carriers, as com-
pared to screening with mammography alone, from the
perspective of the British Columbia healthcare system,









Figure 1 Markov model for annual breast cancer screening with MRI
or “Mammography” and alternate every 6 months (in the mammography alon
screen). Women with positive screening results move through the right side o
while cancer cases continue to treatment, by stage at diagnosis. Women with
screened once more; if their cancer remains undetected they are classified asMethods
Model design
An advisory panel of clinicians, program managers and re-
searchers was established to support this study. The inves-
tigators constructed a Markov model to determine the
cost per QALY gained with current MRI and mammog-
raphy screening practices, comparing annual mammog-
raphy alone to annual mammography and MRI (Figure 1),
from the perspective of the healthcare system. The model
simulates a cohort of women beginning at age 25 years,
with a 6-month cycle length, representing the current time
between screens, and a lifetime time horizon. The model
represents screening, diagnostics and treatment for a
woman’s first breast cancer; screening for second primary
cancers is not considered.
In the mammography plus MRI screening strategy,
women alternate between MRI and mammography screen-
ing every six months (Figure 1). In current practice at the
BCCA high-risk screening clinic, MRI is offered from ages
25–64 years, and mammography screening is offered from
ages 30–79 years; thus in the mammography plus MRI
strategy, women aged 25–29 years receive only MRI
screening, and women 65–79 years receive only mammog-
raphy. In the mammography alone strategy, women are









and Mammography. Women begin in the Markov stages “MRI screen”
e arm, the “MRI screen” state is replaced with a 6-month interval with no
f the model; those with no cancer (false positives) return to screening,
cancer whose screening results are negative (false negatives) are
having non-screen-detected cancers, and proceed through treatment.
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itives) proceed through diagnostic work-up to treatment;
women with false positive screen results also undergo a
diagnostic work-up but return to screening. Any women
with incident cancer that is not detected by screening re-
main in the screening health states for a further 6 months;
if their cancer remains undetected (that is, if in the MRI
arm their subsequent screen is also negative, or if in the
mammography alone strategy they do not receive a screen
within those 6 months), they are classified as having clinic-
ally manifesting non-screen-detected cancer.
Cancer treatments and outcomes by stage at diagnosis
are the same across both strategies of the model. In the
model, patients undergo treatment for the first 18
months following diagnosis, or until they die or transi-
tion to progressive disease, whichever is shorter. Patients
who die of cancer within 18 months (3 cycles) of diagno-
sis transition to the ‘dead’ health state without moving
through the ‘progressive disease’ state, while those who
die in subsequent cycles are assumed to have experi-
enced progressive disease for the last 18 months (3 cy-
cles) prior to death [25]. In the model, patients with in
situ disease do not progress to invasive disease, and all
patients who survive at least 10 years after diagnosis are
no longer at risk of progression.
Transition probabilities
Age-specific breast cancer incidence in the BRCA1 and
BRCA2 populations [2] was weighted to represent mutation
frequency at the BCCA (59% BRCA1 and 41% BRCA2;
Table 1). Sensitivity and specificity values for the mammog-
raphy plus MRI arm were taken from a meta-analysis of
MRI screening effectiveness studies [16]. The sensitivity of
MRI or mammography given a prior false negative screen
with the opposite modality was calculated using the
reported sensitivity values for each screening modality
alone and the sensitivity of detection by either MRI or
mammography when both are offered together. Using these
values, we were able to solve for the joint probability of de-
tection by both MRI and mammography, and derive esti-
mates for the conditional probability of detection by MRI
given a false negative from mammography, and vice versa.
For the mammography alone strategy, age-specific sensitivity
and specificity values were used [26] to account for the early
onset of breast cancer among BRCA1/2 carriers and the de-
creased sensitivity of mammography in younger women. The
stage distributions of MRI-detected and mammogram-
detected cancers in the BRCA1/2 population were synthe-
sized using Dirichlet distributions for stage at diagnosis
[11-13,27]. For clinically manifesting, non-screen-detected
cancers, the historical stage distribution prior to screening
was used [28]. In the model, stage distribution for screen-
detected cancers was based only on method of detection,
and was independent of prior screening.Local survival rates for the general breast cancer popula-
tion were calculated using data from the BC Cancer Regis-
try (including linked deaths data from the BC Vital
Statistics Agency), and were fitted to a series of Weibull
distributions [29] by the Surveillance and Outcomes Unit
of the BCCA to generate the transition probabilities for
the cancer outcomes in the model. The advisory panel val-
idated this decision; the literature suggests that survival
among BRCA1/2 carriers with breast cancer is no worse
than for mutation-free controls [30]. Transition through
the progressive disease state before death, described above,
was implemented by introducing an 18-month lead time
to the calculated survival curves. Published estimates of
competing mortality in the BRCA1/2 population were also
incorporated into the model [31].
Costs
All costs included in the model are summarized in Table 2.
The cost of mammography screening was estimated from
the BC Medical Services Commission Fee Schedule for
2008 [32]. MRI screening cost was calculated as the mean
of three cost estimates provided by the BCCA and two
regional health authorities. The cost included radiologist,
technologist and clerical staff costs, materials, support
costs, and overhead. The cost of a diagnostic work-up
was calculated as the weighted mean cost of consultations,
diagnostic mammography, ultrasound, fine needle aspir-
ation, core biopsy, and open biopsy delivered following ab-
normal screen results, using observed frequencies reported
from the provincial screening program [33] and local unit
cost estimates [32,34].
We calculated treatment costs in the model using re-
cords from the BC Cancer Agency database (CAIS) for all
breast cancer patients who underwent mutation testing at
the Hereditary Cancer Program between 2002 and 2007
and were found to be BRCA1 or BRCA2 mutation carriers
(n = 68). Surgery, radiotherapy and systemic therapy in
the first 18 months following diagnosis were included
in the cost calculation [32,35-37] and fitted to gamma dis-
tributions [29]. Costs were calculated separately for three
6-month intervals (from months 1–6, 7–12, and 13–18 fol-
lowing diagnosis) to correspond with model cycle length
and ensure appropriate allocation of costs over time. Using
the subset of patients who died of breast cancer before
January 2009 (n = 10) we calculated the cost of radiother-
apy and systemic therapy received in the last 18 months of
life (as three 6-month intervals), and estimated costs of
additional hospitalization, using published length of stay
and per-diem costs [36,37].
Utilities
Standard gamble utility weights obtained from the litera-
ture for breast cancer treatment by stage at diagnosis
were applied for up to 18 months while patients were in
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months a remission utility was applied to all cancer stages,
until transition to progressive disease or return to full
health after 10 years. The screening and interval health
states were assumed to have a utility value of 1.0. The util-
ity for a diagnostic workup was derived from a published
value for diagnostic mammography, and lasted for two
weeks of the 6 month cycle [39]. Utilities for remission
and diagnostic mammography, which had been measured
using a visual analog scale, were scaled up to approximate
standard gamble values [39,40].Table 1 Model inputs for transition probabilities for cancer in
Incidence








MRI and Mammography [16] 94 90-97
MRI 77 70-84
MRI given false negative mammogram 90 87-93*
Mammography 39 37-41
Mammography given false negative MRI 74 68-80*





Stage distribution MRI-detected [11-13,27]†
% 95% CI










* 95% CIs for conditional probabilities were estimated by sampling from beta distri
each modality alone, and solving for the conditional probability.
† Calculated using cancers pooled from studies of MRI and mammography screenin
‡ estimated from Weibull distribution parameters provided by BCCA Surveillance anAnalysis
The model was analyzed using TreeAge Pro 2012, 1.3.0.
The model design was clinically validated by members of
the advisory panel, and model estimates of incidence
and mortality were verified against published values. We
conducted a cost-effectiveness analysis to calculate the in-
cremental cost effectiveness ratio (ICER) of screening with
MRI, expressed as 2008 CAD$ per quality-adjusted life
year (QALY). Costs and utilities were discounted at 3.5%
per year [41]. Probabilistic sensitivity analysis was










Mammography detected [11-13,27]† Non-screen detected [28]
% 95% CI % 95% CI
27 17-38 5 3-6
49 38-58 48 46-50
22 12-31 40 37-42







butions for sensitivity of MRI and mammography combined and sensitivity for
g added to a uniform Dirichlet distribution.
d Outcomes Unit for the general breast cancer population.
Table 2 Costs of screening, diagnostics and treatment
Screening and diagnostics Cost ($) 95% CI
MRI screen 277 196-376
Bilateral mammogram 95 55-146
Diagnostic work-up 187 106-292
Total treatment cost Cost ($) 95% CI*




Progression (end of life) 26,704 11,851-47,489
Abbreviations: CI Confidence interval.
* Patient-level total costs were fitted to gamma distributions to generate 95% CI.
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tainty was represented by plotting all results on the cost-
effectiveness plane and by using the cost effectiveness
acceptability curve, which illustrates the probability that
MRI screening is cost-effective for a given range of willing-
ness to pay values [29]. Cost-effectiveness was evaluated at
example willingness to pay values of $50,000 and $100,000
per QALY. One-way sensitivity analysis was also conducted
for the cost of MRI, sensitivity and specificity of MRI, stage
of MRI-detected cancers, and discount rate to evaluate
their impact on the ICER.
Ethical approval for this study was provided by the Uni-
versity of British Columbia-BC Cancer Agency Research
Ethics Board.Table 3 Health state utility weights
Screening and diagnostics 95% CI
MRI screening* 1.000 -
Mammography 1.000 -
Diagnostic workup 0.987 0.761-1.00
Treatment†








Abbreviations: CI Confidence interval.
* Full utility (1.00) assumed for screening states and ‘Well’ state; not varied in
probabilistic sensitivity analysis.
† Treatment utilities by stage at diagnosis applied for 18 months, after which
‘Remission’ value applied until progression and death or transition to ‘Well,’ 10-yrs
post-diagnosis; utilities for localized, regional, distant disease, and disease
progression states were derived from Schleinitz et al. [38], and utility for
diagnostic work-up, remission and in situ disease were from Bonomi et al. [39].Results
After modeling a BRCA1/2 cohort from age 25 years, the
cumulative risk of developing breast cancer by age 65
years was 42.7% (95% CI: 38.8, 46.7) (Table 4). This was
slightly lower but generally comparable to cumulative inci-
dence estimated from Antoniou et al. [1] and Chen and
Parmigiani [2] (50.4% and 45.4% respectively), and consid-
ered a valid approximation. Mortality was slightly reduced
with the addition of MRI, with 80.1% (95% CI: 78.9, 81.1)
vs. 79.1% (95% CI: 77.4, 80.4) of women surviving to age
65. Mortality approximated values from Byrd et al. [42];
using data from that study, an estimated 22% of female
BRCA1/2 mutation carries died before age 65 years from
breast cancer or other causes, excluding ovarian cancer.
With the addition of MRI to annual mammography
screening, 93.9% (95% CI: 89.4, 97.3) of cancers that devel-
oped by age 65 years were screen-detected, compared
to 71.7% (95% CI: 65.9, 77.2) with mammography alone.
Cancers in the MRI plus mammography arm were less
likely to be either regional or distant, and more likely to be
localized than in the mammography alone arm.
Cost-effectiveness analysis gave an incremental cost of
MRI screening of $4692 (95% CI: 3084, 7910) per partici-
pant, with 0.092 QALYs gained (95% CI: -0.027, 0.190),
resulting in a mean ICER of $50,911/QALY (Table 4). The
scatter plot of incremental cost and effectiveness values
for each simulation is shown in Figure 2; in 3.9% of simu-
lations, the MRI screening strategy was less effective than
mammography alone. The cost-effectiveness acceptability
curve (Figure 3) indicates that if a decision maker were
willing to pay $100,000 per QALY gained, MRI screening
is a cost-effective option 85.6% of the time. At a willing-
ness to pay of $50,000/QALY, it is cost-effective 52.6% of
the time.
One-way sensitivity analysis indicated that the model
was somewhat sensitive to changes in the effectiveness of
MRI screening – measured as MRI sensitivity, MRI specifi-
city and stage distribution of MRI-detected cancers – but
very sensitive to the cost of an MRI scan (Figure 4). As cost
was varied from $200-$700, the ICER ranged widely, from
$37,119 to $132,944 per QALY.Discussion
In our model, annual mammography plus MRI, compared
to annual mammography alone, has an ICER of $50,900
per QALY. This ICER was estimated using local cost and
treatment data, with input from clinicians and decision-
makers on the project’s advisory panel, in an effort to most
accurately depict the context of breast cancer screening
and treatment for BRCA1/2 mutation carriers in British
Columbia. These results suggest that the cost-effectiveness
of the MRI screening program for BRCA1/2 mutation car-
riers is finely balanced, with sensitivity to input parameters
Table 4 Cost-effectiveness and effectiveness of MRI screening vs. annual mammography alone
Cost-effectiveness* Mammography only MRI & mammography Increment
Mean 95% CI Mean 95% CI Mean 95% CI
Cost ($) 5,201 3,303-7,911 9,893 7,459-12,942 4,692 3,084-6,504
QALYs 22.57 21.86-22.75 22.66 21.85-22.83 0.092 −0.027-0.190
C/E ($/QALY) 231 146-351 437 329-572 50,911 Dominated-213,794
Screening effectiveness† Mammography only MRI & mammography
Mean (%) 95% CI Mean (%) 95% CI
Incidence 42.7 38.8-46.7 42.7 38.7-46.7
Program sensitivity‡ 71.7 65.9-77.2 93.9 89.4-97.3
Stage distribution
In Situ 20.8 12.8-30.1 18.2 12.8-24.2
Local 48.7 39.1-58.3 61 53.8-67.8
Regional 26.9 19.6-35.5 19.1 13.9-25.1
Distant 3.6 2-7.2 1.7 0.6-3.8
Survival 79.1 77.4-80.4 80.1 78.9-81.1
Abbreviations: MRI magnetic resonance imaging, QALY quality-adjusted life year.
* Costs and utilities discounted at 3.5% per year.
† Calculated at end of MRI plus mammography screening program (age 65 years).
‡ Proportion of cancers in model detected by screening; all screen-detected cancers (true positives) divided by all incident cancers.
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effectiveness threshold, but the ICER falls within the gener-
ally accepted range for funded programs.
The mammography plus MRI strategy of the model dif-
fers from the mammography alone strategy in four key
ways: the cost of MRI screening, increased screening sen-























Figure 2 Scatter plot of incremental cost and effectiveness for 10,000
MRI, magnetic resonance imaging; QALY, quality-adjusted life-year.detected cancers, and more false positive screens due to
decreased screening specificity. The cost-effectiveness of
MRI screening is highly dependent on the cost of an MRI
scan, as indicated in one-way sensitivity analysis. In situa-
tions where MRI scans are costlier than at the BCCA, MRI
screening for breast cancer may not be a cost-effective op-
tion. However, these results also suggest that improvements0.2 0.4 0.6 0.8 1
ectiveness (QALY)


























Willingness to Pay ($/QALY)
MRI & Mammography
Mammography alone
Figure 3 Cost effectiveness acceptability curve. Abbreviations: MRI, magnetic resonance imaging; QALY, quality-adjusted life-year.
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cost of MRI may reduce the cost-effectiveness of MRI
screening to more acceptable levels.
The time horizon of this model, as with any model of
preventive or screening techniques, also has an impact on
the findings. The costs of MRI screening accrue from the
beginning of model, while the benefits arising from MRI
screening, such as lower treatment costs for cancers
detected at an earlier stage, appear much later in the model,
particularly as the cohort ages and cancer incidence rises.
Consequently, the model is very sensitive to discounting as-
sumptions for cost and QALYs.
The ICER calculated in this study is higher than previ-
ously published cost-effectiveness estimates from the UK,
but lower than those from the US [20-22,24]. In the UK
study by Norman et al., women were screened for only 10Variable name Variable range ICER range
MRI sensitivity 0.85-0.70 43,631-62,904 
MRI specificity 0.95-0.80 45,236-57,676 
In Situ 0.20-0.10 39,049-80,124 
Localized 0.75-0.60 45,780-67,019 
Regional 0.10-0.20 33,190-93,278 
Distant 0.005-0.02 47,491-64,625 
Cost of MRI ($) 200-700 37,119-132,944 
Discount Rate 0-0.06 25,996-85,502 
$20,000
Figure 4 One-way sensitivity analysis and tornado diagram of increm
magnetic resonance imaging; ICER, incremental cost-effectiveness ratio; QAyears, beginning at age 30 or 40 years, giving ICERS of ap-
proximately CAD$17,600 and $30,600 per QALY [24]. By
contrast, our model includes MRI screening from age 25
to 65 years. In the US studies, the cost of MRI was much
higher than in this study, around USD$1000 for a bilateral
screen, which is a potential reason why the reported
ICERs are also higher. Moore et al. found in their sensitiv-
ity analysis that reducing the cost of MRI to below USD
$315 resulted in an ICER of under USD$50,000/QALY,
down from the base-case ICER of nearly USD$180,000/
QALY, which is more consistent with the findings of this
study [22]. Both Moore’s model and this study highlight
the fact that MRI screening for breast cancer may be cost
effective, when the cost of MRI scans is low.
A limitation of this model is that it represents an ideal-
ized screening program, with all women entering at age 25$50,000 $80,000 $110,000 $140,000
ICER ($/QALY)
ental cost-effectiveness of MRI screening. Abbreviations: MRI,
LY, quality-adjusted life year.
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The MRI screening program operated by the BCCA has a
dynamic population. Women join the program at various
ages when they are deemed to be eligible, and leave after
undergoing prophylactic surgery, after developing cancer,
or for other reasons. The timing of screening also varies:
women who must travel to Vancouver for screening often
have both MRI and mammography done concurrently, and
the interval between MRI screens may exceed 12 months.
Consequently, the cost-effectiveness of the screening pro-
gram, if it were to be measured using real-world, compara-
tive effectiveness program data, may be different. Although
our goal was to use as much local data as possible, the
challenge of acquiring comparative effectiveness data to in-
form the model was a further limitation of this study. We
had insufficient sample size and follow-up to fully evaluate
the effectiveness of the BCCA’s MRI screening program.
We instead relied on the literature for screening effective-
ness data. A further limitation of the model is that we were
unable to include the risk of overdiagnosis from additional
screening with MRI. Estimates of overdiagnosis attributable
to mammography screening vary widely, from under 10%
to as high as 50% [43-46]; however, overdiagnosis from
MRI screening has not been assessed, nor has the rate of
overdiagnosis in the BRCA1/2 population.
The model that we constructed to assess the cost-
effectiveness of MRI screening lays the foundation to po-
tentially address other questions related to breast cancer
screening. For example, as more data become available the
model could be adapted to find the optimal start time and
duration of MRI screening from a cost-effectiveness per-
spective, or to investigate the relationship between lifetime
breast cancer risk and cost-effectiveness of MRI screening,
exploring the feasibility of expanding MRI screening to
other high-risk groups.
Conclusions
Annual mammography plus MRI screening of BRCA1/2
mutation carriers at the BCCA was found to be potentially
cost-effective, with an ICER of $50,900/QALY when com-
pared to annual mammography alone, although the cost-
effectiveness is finely balanced. The benefits of early
detection of breast cancer with MRI in this population
may outweigh the added cost of screening and the higher
risk of false positives; however, the cost-effectiveness of
MRI screening is highly dependent on the cost of MRI
scans and there remains some statistical uncertainty
around the results.
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